Please wait

 

.2

img193038000_0.jpg

 

Arcadia Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

 

 

 

 

 

 

 

 

 

 

September 30, 2025

 

 

December 31, 2024

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,120

 

 

$

4,242

 

Short-term investments

 

 

4,765

 

 

 

 

Accounts receivable and other receivables, net of allowance for credit losses of
   $559 and $0 as of September 30, 2025 and December 31, 2024, respectively

 

 

831

 

 

 

1,175

 

Inventories

 

 

1,457

 

 

 

904

 

Note receivable — current, net of allowance for credit losses (Note 7)

 

 

 

 

 

1,894

 

Prepaid expenses and other current assets

 

 

214

 

 

 

931

 

Current assets of discontinued operations — GoodWheat

 

 

 

 

 

96

 

Total current assets

 

 

8,387

 

 

 

9,242

 

Property and equipment, net

 

 

10

 

 

 

41

 

Right of use asset

 

 

 

 

 

137

 

Intangible assets, net

 

 

39

 

 

 

39

 

Note receivable — noncurrent, net of allowance for credit losses (Note 7)

 

 

 

 

 

3,966

 

Other noncurrent assets

 

 

148

 

 

 

92

 

Total assets

 

$

8,584

 

 

$

13,517

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

2,015

 

 

$

2,108

 

Amounts due to related parties

 

 

 

 

 

30

 

Operating lease liability — current

 

 

 

 

 

155

 

Other current liabilities

 

 

270

 

 

 

270

 

Total current liabilities

 

 

2,285

 

 

 

2,563

 

Common stock warrant and option liabilities

 

 

856

 

 

 

2,731

 

Other noncurrent liabilities

 

 

 

 

 

2,000

 

Total liabilities

 

 

3,141

 

 

 

7,294

 

Commitments and contingencies (Note 14)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value—150,000,000 shares authorized as
   of September 30, 2025 and December 31, 2024; 1,367,429 and 1,364,940 shares issued
   and outstanding as of September 30, 2025 and December 31, 2024, respectively

 

 

65

 

 

 

65

 

Additional paid-in capital

 

 

285,259

 

 

 

285,036

 

Accumulated deficit

 

 

(279,881

)

 

 

(278,878

)

Total stockholders' equity

 

 

5,443

 

 

 

6,223

 

Total liabilities and stockholders’ equity

 

$

8,584

 

 

$

13,517

 

 

1


 

 

 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except share data and per share data)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

1,302

 

 

$

1,537

 

 

$

3,957

 

 

$

3,829

 

Total revenues

 

 

1,302

 

 

 

1,537

 

 

 

3,957

 

 

 

3,829

 

Operating expenses (income):

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

884

 

 

 

1,032

 

 

 

2,389

 

 

 

2,136

 

Research and development

 

 

 

 

 

24

 

 

 

9

 

 

 

40

 

Gain on sale of intangible assets

 

 

 

 

 

 

 

 

(750

)

 

 

(4,000

)

Impairment of property and equipment

 

 

 

 

 

 

 

 

 

 

 

36

 

Change in fair value of contingent consideration

 

 

 

 

 

 

 

 

(2,000

)

 

 

 

Selling, general and administrative

 

 

1,570

 

 

 

2,241

 

 

 

5,434

 

 

 

6,986

 

Total operating expenses

 

 

2,454

 

 

 

3,297

 

 

 

5,082

 

 

 

5,198

 

Loss from operations

 

 

(1,152

)

 

 

(1,760

)

 

 

(1,125

)

 

 

(1,369

)

Interest income

 

 

7

 

 

 

233

 

 

 

222

 

 

 

428

 

Credit loss

 

 

(257

)

 

 

 

 

 

(4,745

)

 

 

 

Other income

 

 

1,698

 

 

 

15

 

 

 

2,770

 

 

 

168

 

Change in fair value of common stock warrant and option liabilities

 

 

560

 

 

 

330

 

 

 

1,875

 

 

 

493

 

Net income (loss) from continuing operations

 

 

856

 

 

 

(1,182

)

 

 

(1,003

)

 

 

(280

)

Net loss from discontinued operations

 

 

 

 

 

(430

)

 

 

 

 

 

(2,694

)

Net income (loss) attributable to common stockholders

 

$

856

 

 

$

(1,612

)

 

$

(1,003

)

 

$

(2,974

)

Net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic from continuing operations

 

$

0.63

 

 

$

(0.87

)

 

$

(0.73

)

 

$

(0.21

)

Basic from discontinued operations

 

$

 

 

$

(0.32

)

 

$

 

 

$

(1.98

)

Net income (loss) per basic share attributable to common stockholders

 

$

0.63

 

 

$

(1.18

)

 

$

(0.73

)

 

$

(2.18

)

Diluted from continuing operations

 

$

0.62

 

 

$

(0.87

)

 

$

(0.73

)

 

$

(0.21

)

Diluted from discontinued operations

 

$

-

 

 

$

(0.32

)

 

$

-

 

 

$

(1.98

)

Net income (loss) per diluted share attributable to common stockholders

 

$

0.62

 

 

$

(1.18

)

 

$

(0.73

)

 

$

(2.18

)

Weighted-average number of shares used in per share
   calculations:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

1,367,192

 

 

 

1,363,753

 

 

 

1,366,768

 

 

 

1,362,754

 

Diluted

 

 

1,371,879

 

 

 

1,363,753

 

 

 

1,366,768

 

 

 

1,362,754

 

Other comprehensive income, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gains on available-for-sale securities

 

$

 

 

$

36

 

 

$

 

 

$

117

 

Reclassification adjustment for gains on available-for-sale securities included in net income (loss)

 

 

 

 

 

 

 

 

 

 

 

(111

)

Change in unrealized gains on available-for-sale securities

 

$

 

 

$

36

 

 

$

-

 

 

$

6

 

Comprehensive income (loss)

 

$

856

 

 

$

(1,576

)

 

$

(1,003

)

 

$

(2,968

)

 

2


 

Arcadia Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Nine Months Ended September 30,

 

 

 

 

2025

 

 

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(1,003

)

 

$

(2,974

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Change in fair value of common stock warrant and option liabilities

 

 

(1,875

)

 

 

(493

)

Change in fair value of contingent consideration

 

 

(2,000

)

 

 

 

Depreciation

 

 

30

 

 

 

92

 

Lease amortization

 

 

122

 

 

 

502

 

Amortization of note receivable

 

 

(69

)

 

 

(90

)

Gain on disposal of property and equipment

 

 

 

 

 

(65

)

Gain on sale of RS durum wheat trait

 

 

(750

)

 

 

(4,000

)

Gain on receipt of Above Food Ingredients, Inc. common stock

 

 

(1,067

)

 

 

 

Unrealized gain subsequent to receipt of Above Food Ingredients, Inc. common stock

 

 

(1,698

)

 

 

 

Stock-based compensation

 

 

217

 

 

 

395

 

Credit loss

 

 

4,745

 

 

 

 

Write-down of inventories

 

 

 

 

 

154

 

Impairment of property and equipment

 

 

 

 

 

36

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable and other receivables

 

 

(241

)

 

 

(445

)

Inventories

 

 

(552

)

 

 

620

 

Prepaid expenses and other current assets

 

 

717

 

 

 

287

 

Other noncurrent assets

 

 

(56

)

 

 

 

Accounts payable and accrued expenses

 

 

(172

)

 

 

(719

)

Amounts due to related parties

 

 

(30

)

 

 

(29

)

Other current liabilities

 

 

(57

)

 

 

(11

)

Operating lease liabilities

 

 

(139

)

 

 

(678

)

Net cash used in operating activities

 

 

(3,878

)

 

 

(7,418

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Proceeds from sale of intangible assets

 

 

750

 

 

 

 

Proceeds from sale of property and equipment

 

 

 

 

 

342

 

Proceeds from sale of investments

 

 

 

 

 

2,501

 

Proceeds from sale of RS durum wheat trait

 

 

 

 

 

4,000

 

Cash paid related to sale of GoodWheat

 

 

 

 

 

(2,000

)

Purchases of property and equipment

 

 

 

 

 

(16

)

Net cash provided by investing activities

 

 

750

 

 

 

4,827

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from ESPP purchases

 

 

6

 

 

 

9

 

Net cash provided by financing activities

 

 

6

 

 

 

9

 

Net decrease in cash and cash equivalents

 

 

(3,122

)

 

 

(2,582

)

Cash and cash equivalents — beginning of period

 

 

4,242

 

 

 

6,518

 

Cash and cash equivalents — end of period

 

$

1,120

 

 

$

3,936

 

NONCASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

Right of use assets obtained in exchange for new operating lease liabilities

 

$

 

 

$

86

 

Fair value of Above Food Ingredients, Inc. common stock received

 

$

3,067

 

 

$

 

 

# # #

3